France· FR:64933044
CELSENTRI 75 mg, comprimé pelliculé
A maraviroc product containing maraviroc, registered in France by VIIV HEALTHCARE UK (ROYAUME-UNI), on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Maraviroc is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX09 (maraviroc), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Maraviroc · ATC J05AX09
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of maraviroc costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $25.28 in France to $84.16 in United States — a ×3.3 gap.
- France: $25.28 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Maraviroc · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- US United States$84.16 (acquisition cost)
- CH Switzerland$55.16
- FR France$25.28
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MARAVIROC
- Manufacturer
- VIIV HEALTHCARE UK (ROYAUME-UNI)
- Country
- France (FR)
- ATC code
- J05AX09
- ATC class
- Maraviroc
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009301033881 flacon(s) polyéthylène haute densité (PEHD) aluminium avec fermeture de sécurité enfant de 120 comprimé(s)EUR 378.04
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for maraviroc.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Maraviroc · interactions on record
143 records
- 14 severe
- 129 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- CeritinibL01ED02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Maraviroc in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCelsentri 75 mgViiV Healthcare
- CzechiaCELSENTRIViiV Healthcare BV, Amersfoort
- FinlandCELSENTRIViiV Healthcare BV
- IrelandCelsentri 75 mg Film-coated tabletViiV Healthcare BV
- IcelandCelsentriViiV Healthcare BV
- PolandCelsentriViiV Healthcare BV
- SwedenCELSENTRI 75 mg Filmdragerad tablettViiV Healthcare BV
- United StatesMaravirocZydus Pharmaceuticals USA Inc.
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Maraviroc
- Germany · Maraviroc, Maraviroc Amarox
- Spain · Maraviroc Tarbis, Maraviroc Waymade
- United Kingdom (Northern Ireland) · Maraviroc Amarox Limited, Maraviroc Waymade
- Iceland · Celsentri
- Italy · Maraviroc Waymade
- Liechtenstein · Celsentri
- Netherlands · Maraviroc, Maraviroc Amarox
- Norway · Celsentri
- Portugal · Maraviroc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5ae4fd12-8459-4623-88c9-694d485dec47 GET /v1/drugs/5ae4fd12-8459-4623-88c9-694d485dec47?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64933044",
"date_amm": "2017-07-06",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/07/418",
"substance": "MARAVIROC",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about maraviroc.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.